anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
) The invention relates to a ion silver-plated zeolite which constitutes zeolite with size of the particles of 60-100 µm and size of the pores of 3-4 A, containing silver ions 0.03 mg/g to 3 mg/g. The preparation method, according to the invention, consists of the following: А) deionized water is electrolytically saturated with silver ions by applying electricity with a voltage of 8-10 V on silver electrodes for a period of 0.5 to 2 hours until concentrations of 0.03 mg/l to 3 mg/l are achieved. B) natural zeolite is subjected to grinding and sieving up to a fraction of 60-100 µm. After this, it is washed with a 5% solution of sodium chloride. A second wash with deionized water follows, until the chloride ions are removed. The zeolite washed in this way is heat-activated by heating at 400-450°С for 2-3 hours until the complete release of the zeolite water. C) Next follows mixing of the 3-4 A zeolite with the water saturated with ion silver for a period of 1 to 2 hours, under vigorous stirring, in a ratio of silver water from 0.03 mg/l to 3 mg/l : zeolite 1 g. The mixture is filtered in a vacuum with a 50 µm filter. The drying occurs at 25°С until the complete removal of the moisture. The ion silver-plated zeolite, according to the invention, is intended for use in human and veterinary medicine as an antibacterial and antimicrobial means. For internal use with a maximum density of ion silver from 0.03 mg/g to 0.1 mg/g and for external use from 1 mg/g to 3 mg/g, whereby one part of the pores of the zeolite remain free, which multiplies its drying effect and ability for additional ion exchange, releasing its sodium or calcium ions, together with a sufficient amount of silver ions. Advantages of the method – economical, high temperatures are not applied, additional agents are not used which makes it environmentally friendly, allows for controlling the amount of silver ions adsorbed in the zeolite, ensures the preparation of a product which is suitable for use in medicine, whereby it possesses the ability to release the biocide agent at a predetermined rate and optimal bioavailability in the treated organism.
The invention discloses a bandage with an application tape for pelvic floor dysfunction. Belongs to the technical field of medical appliances. The method comprises the following steps: the bandage main part of "worker" style of calligraphy, paste part, pubis calibration reference point, solid fixed ring can dismantle and apply ointment or plaster. The medicine in the detachable application comprises the following raw materials: raw astragalus, fructus psoraleae, fructus alpiniae oxyphyllae, mantis egg-case, semen cuscutae, cherokee rose fruit, cinnamon, dendrobium officinale extract, carbomer gel and propylene glycol. The invention realizes the comprehensive treatment of the pelvic floor dysfunction by comprehensive application of biomechanics and pharmacology. Under the action of maximum external force, the closed reduction of the pelvic floor within 30 days reaches 90%, and the supporting effect of I type collagen of rectus abdominis and pelvic floor muscles and the tissue elasticity of III type collagen are effectively improved through the transdermal absorption of the medicine application. Can obviously improve the mechanical property of the pelvic floor support structure and repair the rectus abdominis, pelvic floor muscles and connective tissues.
Analog-to-feature (A2F) conversion based on non-uniform wavelet sampling (NUWS) has demonstrated the ability to reduce energy consumption in wireless sensors while employed for electrocardiogram (ECG) anomaly detection. The technique involves extracting only relevant features for a given task directly from analog signals and conducting classification in the digital domain. Building on this approach, we extended the application of the proposed generic A2F converter to address a human activity recognition (HAR) task. The performed simulations include the training and evaluation of neural network (NN) classifiers built for each application. The corresponding results enabled the definition of valuable features and the hardware specifications for the ongoing complete circuit design. One of the principal elements constituting the developed converter, the integrator brought from the state-of-the-art design, was modified and simulated at the circuit level to meet our requirements. The revised value of its power consumption served to estimate the energy spent by the communication chain with the A2F converter. It consumes at least 20 and 5 times less than the chain employing the Nyquist approach in arrhythmia detection and HAR tasks, respectively. This fact highlights the potential of A2F conversion with NUWS in achieving flexible and energy-efficient sensor systems for diverse applications.
Patients receive pembrolizumab IV over 30 minutes on day 1 and undergo radiation therapy BID 5 days a week for 3 weeks. Patients also receive cisplatin IV over 2 hours or carboplatin IV over 30 minutes and etoposide IV over 4 hours on days 1, 2, and 3. Treatment repeats every 3 weeks for 16 courses (1 course for radiation therapy, 4 courses for chemotherapy) in the absence of disease progression or unacceptable toxicity. Patients who achieve systemic disease control and do not exhibit severe (grade \> 3) pembrolizumab related toxicity during/after completion of 16 courses may receive 16 additional courses of pembrolizumab in the absence of disease progression or unacceptable toxicity.
PURPOSE:To provide a cosmetic having excellent feeling, giving excellent finished skin and stable in dermatological point of view. CONSTITUTION:The objective cosmetic contains an alkenylsuccinic acid ester of a sugar produced by reacting a sugar with an alkenylsuccinic anhydride such as octenylsuccinic anhydride as a cosmetic base material. The sugar to be used as a starting raw material is monosaccharide, oligosaccharide, hydrolyzed starch, amino sugar, acidic sugar, sugar alcohol, saccharified reduced starch, reduced maltose syrup, etc. The amount of the alkenylsuccinic acid ester of sugar is preferably 0.1-15wt.% for a hair-care cosmetic such as shampoo and rinse and 0.5-30wt.% for a skin-care cosmetic such as cream. The compound has high affinity to the hair and skin and excellent film-forming property and adsorptivity to the hair, etc. The effect of the compound as protecting colloid can be maintained even by the addition of other surfactant to enable the combined use of other surfactants.
Niacin

Niacin functions in the body after conversion to nicotinamide adenine dinucleotide (NAD) in the NAD coenzyme system. The mechanism by which niacin alters lipid profiles is not completely understood and may involve several actions, including partial inhibition of release of free fatty acids from adipose tissue, and increased lipoprotein lipase activity (which may increase the rate of chylomicron triglyceride removal from plasma). Niacin decreases the rate of hepatic synthesis of VLDL-C and LDL-C, and does not appear to affect fecal excretion of fats, sterols, or bile acids.

Simvastatin

Simvastatin is a prodrug and is hydrolyzed to its active ß-hydroxyacid form, simvastatin acid, after administration. Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in the biosynthetic pathway for cholesterol. In addition, simvastatin reduces VLDL and TG and increases HDL-C.
Porous polymers having a plurality of openings or chambers that are highly convoluted, with each chamber being defined by multiple, thin, flat partitions are produced by a new gel enhanced phase separation technique. In a preferred embodiment, a second solvent is added to a polymer solution, the second solvent causing the solution to gel. The gel can then be shaped as needed. Subsequent solvent extraction leaves the porous polymeric body of defined shape. The porous polymers have utility as medical prostheses, the porosity permitting ingrowth of neighboring tissue. A second polymer material may be incorporated into the chambers, thereby creating a microstructure filling the voids of the macrostructure. A porous polymeric body manufactured by this process may serve to deliver biologically active agents in a time-staged delivery manner, where differing drugs may be delivered over differing periods.
The invention relates to medicinal and edible hangover-relieving capsules which can be used as an instant hangover-relieving food after hangover caused by excessive alcohol taken in vacation parties, official circles and the business fields. The capsules are a medicinal and edible health-care product causing no side effect. The capsules provide reparation and nourishing functions upon damaged liver cells. With the capsules, liver-protecting and detoxifying functions are realized through a pharmacological effect of improving alcohol dehydrogenase activity. The components of chitosan, ganoderan, and lobed kudzuvine flower bud are obtained through 25 years of clinical researches. As a result of considerable evidences, the capsules are the only scientifically proved liver-nourishing and liver-protecting nutritious food.
A method to follow the progression of metastasis of a primary tumor, which method comprises removing fresh organ tissues from a vertebrate subject which has been modified to contain tumor cells that express GFP and observing the excised tissues for the presence of fluorescence is disclosed. The fluorescence can also be monitored by observing the tissues in situ. Vertebrate subjects which contain GFP producing tumors are useful models to study the mechanism of metastasis. In addition, subjects already harboring tumors can be treated so as to modify the endogenous tumors to contain GFP. This permits clinical applications. Finally, by injecting a contrast dye into a subject harboring a GFP-labeled tumor, angiogenesis in the tumor can be observed directly.
In the first interview, the patients in the control group will be collected data and contact information will be obtained using the Patient Information Form, Exercise Change Phase Short Question Form, Change Processes Scale, Decision Making Balance Scale and Self-Efficacy Scale. Later, patients will be given their username and password so that they can log into the website where the scales are located in order to apply the final test. No intervention will be applied to the patients in the control group. At the end of the 6th month, the same scales will be applied on the website as a final test. At the end of the study, it is aimed to gain exercise behavior to the patients in the control group.
Marine fishes excrete excess H+ using basolateral Na+-K+-ATPase (NKA) and apical Na+/H+ exchanger 3 (NHE3) in gill ionocytes. However, the mechanisms that regulate H+ excretion during exposure to environmentally relevant hypercapnia (ERH) remain poorly understood. Here, we explored transcriptomic, proteomic, and cellular responses in gills of juvenile splitnose rockfish (Sebastes diploproa) exposed to 3 days of ERH conditions (pH ∼7.5, ∼1,600 μatm Pco2). Blood pH was fully regulated at ∼7.75 despite a lack of significant changes in gill 1) mRNAs coding for proteins involved in blood acid-base regulation, 2) total NKA and NHE3 protein abundance, and 3) ionocyte density. However, ERH-exposed rockfish demonstrated increased NKA and NHE3 abundance on the ionocyte plasma membrane coupled with wider apical membranes and greater extension of apical microvilli. The observed gill ionocyte remodeling is consistent with enhanced H+ excretion that maintains blood pH homeostasis during exposure to ERH and does not necessitate changes at the expression or translation levels. These mechanisms of phenotypic plasticity may allow fishes to regulate blood pH during environmentally relevant acid-base challenges and thus have important implications for both understanding how organisms respond to climate change and for selecting appropriate metrics to evaluate its impact on marine ecosystems.NEW & NOTEWORTHY Splitnose rockfish exposed to environmentally relevant hypercapnia utilize existing proteins (rather than generate additional machinery) to maintain homeostasis.
The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR  grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.
<P>PROBLEM TO BE SOLVED: To obtain a cell propagation agent containing a platelet-derived growth factor and a vascular endothelial growth factor from a liquid to be treated containing the platelets and leukocytes; and to provide a method for producing the cell propagation agent.  <P>SOLUTION: The method for producing the cell propagation agent comprises a capturing step, an activation treatment step of the platelets, an incubation step of the leukocytes and a collecting step. In the capturing step, the liquid to be treated containing the platelets and the leukocytes is passed through a filter material capable of capturing the platelets and the leukocytes to capture the platelets and the leukocytes in the liquid to be treated by the filter material. In the activation treatment step of the platelets, the activation treatment of the platelets captured by the filter material is carried out to allow the platelets to secrete the platelet-derived growth factor. In the incubation step of the leukocytes, which is carried out after or before the activation treatment step of the platelets, the leukocytes captured by the filter material are incubated to allow the leukocytes to secrete the leukocyte-derived growth factor. In the collecting step, the platelet-derived growth factor and the leukocyte-derived growth factor are collected to afford the cell propagation agent.  <P>COPYRIGHT: (C)2004,JPO
The participants will ingest 600 mg of placebo in two capsules two times a day i.e. 1200 mg/day during a period of one year.
This systematic review collected evidence on the burden of non-communicable diseases (NCDs) among professional drivers and reported on the most common factors that increase the risk of NCDs in this specific population in low- and middle-income countries (LMICs). The protocol for this systematic review was registered in the International Prospective Register of Systematic Reviews (PROSPERO). We conducted a thorough search on PubMed/MEDLINE, EMBASE, Scopus, Global Health, Web of Science and Africa-wide information databases on 11 May 2023. We adapted the Joanna Briggs Institute (JBI) tool to assess the quality of the studies. We estimated the prevalence of hypertension, prediabetes, diabetes mellitus (DM), overweight and obesity among professional drivers using a random effect model to compute pooled and subgroup analyses. In addition, we conducted a narrative synthesis of the risk factors and recommendations presented in the included studies. Forty-one studies, including 48 414 study participants, met the criteria for inclusion. The pooled prevalence of hypertension, DM and obesity among professional drivers was 36.7% [95% confidence interval (CI): 31.8-41.6%], 15.2% (95% CI: 7.0-23.4%) and 27.2% (95% CI: 18.7-35.8%), respectively. Unsupportive environment, work stress, sedentary lifestyle, consumption of unhealthy foods and shift work were the most common modifiable risk factors reported. Our findings also show a significant burden of hypertension, DM and obesity among professional drivers in LMICs. The prevalence of DM and obesity was two- and three-fold higher than findings in general populations, respectively. Our findings indicate an urgent need for tailored interventions for different occupation-related risk factors for NCDs among professional drivers in LMICs.
The participants will have auricular magnets with a strength of 1800 Gauss applied to specific acupoints in the first treatment phase. This is followed by a 14-day washout period. In the second treatment phase, the participants will have auricular magnets with no magnetic strength applied to the same acupoints.
The starting dosage of VRAYLAR is 1.5 mg orally once daily. The recommended dosage range is 1.5 mg to 6 mg orally once daily. The dosage can be increased to 3 mg on Day 2. Depending upon clinical response and tolerability, further dose adjustments can be made in 1.5 mg or 3 mg increments. The maximum recommended dosage is 6 mg orally once daily. In short-term controlled trials, dosages above 6 mg daily do not confer increased effectiveness sufficient to outweigh dose-related adverse reactions [see Adverse Reactions (6.1), Clinical Studies (14.1)].
The study treatment consists of the combination of BO-112 given intratumorally inside the liver metastasis at the dose of 1gm in 1.2 mL in combination with intravenous pembrolizumab given at the fixed dose of 200 mg. This treatment will be given every 3 weeks, with a maximum duration of 35 cycles (2 years). Of note, during the first cycle, BO-112 will be administered on D1 and D8.
PURPOSE:To prepare a bile acid-adsorbing agent containing an ion exchange resin comprising a specific cross-linked polymer, sufficient in small dosages, lowered in foreign feeling on its oral administration, having high stability against acids, and useful as a hyperlipidemia-treating medicine capable of lowering a cholesterol value in blood. CONSTITUTION:The agent contains an anion exchange resin comprising a cross- linked polymer containing a monomer of the formula (X<-> is a counter ion) and other monomers (e.g. ethylene, propylene, styrene, methyl methacrylate) as constituents. The ion exchange resin is obtained by copolymerizing chloromethyl styrene, the monomer of the formula, a copolymerizable monomer and a cross-linking agent (e.g. divinylbenzene, trivinylbenzene) and subsequently reacting the obtained water-insoluble cross-linked copolymer with pyridine. The monomer of the formula is introduced into the copolymer in an amount of 0-90mol.%, preferably 0-50mol.%, based on the whole monomers.
Patients will have periodic fasting for 4 weeks prior to the treatment cycle. The fasting method involves daily fasts of 14-16hours and restrict eating to an 8-10 hour "eating window" as 2-3 or more meals of balanced diet with 2-3 litres of water and non calorie fluids allover the day.
As the climbing exercise group, the aerobic exercise group will start with a ten minutes body-centered, mind-setting warm-up, followed by 60 minutes of Nordic walking and five minutes cool down. A physiotherapist or sport scientist will instruct and guide the group. Nordic walking will be performed at a moderate pace at varying paths.
Prior to pump implantation and initiation of chronic infusion of baclofen injection, patients must demonstrate a positive clinical response to a baclofen injection bolus dose administered intrathecally in a screening trial. The screening trial employs baclofen injection at a concentration of 50 mcg/mL. A 1 mL syringe (50 mcg/mL) is available for use in the screening trial. The screening procedure is as follows. An initial bolus containing 50 micrograms in a volume of 1 milliliter is administered into the intrathecal space by barbotage over a period of not less than one minute. The patient is observed over the ensuing 4 to 8 hours. A positive response consists of a significant decrease in muscle tone and/or frequency and/or severity of spasms. If the initial response is less than desired, a second bolus injection may be administered 24 hours after the first. The second screening bolus dose consists of 75 micrograms in 1.5 milliliters. Again, the patient should be observed for an interval of 4 to 8 hours. If the response is still inadequate, a final bolus screening dose of 100 micrograms in 2 milliliters may be administered 24 hours later. 

###  Pediatric Patients

The starting screening dose for pediatric patients is the same as in adult patients, i.e., 50 mcg. However, for very small patients, a screening dose of 25 mcg may be tried first.

Patients who do not respond to a 100 mcg intrathecal bolus should not be considered candidates for an implanted pump for chronic infusion.
These youth will not receive Working on Womanhood (WOW) services during academic years 2017-18 and 2018-19 \[Cohort 1\] or 2018-19 and 2019-20 \[Cohort 2\] or after, and will not have contact with WOW clinicians. Control youth will be able to receive all other services available through their school as they normally would, such as access to the school counselor and after school programs.
In this paper, we propose a method for predicting epileptic seizures using a pre-trained model utilizing supervised contrastive learning and a hybrid model combining residual networks (ResNet) and long short-term memory (LSTM). The proposed training approach encompasses three key phases: pre-processing, pre-training as a pretext task, and training as a downstream task. In the pre-processing phase, the data is transformed into a spectrogram image using short time Fourier transform (STFT), which extracts both time and frequency information. This step compensates for the inherent complexity and irregularity of electroencephalography (EEG) data, which often hampers effective data analysis. During the pre-training phase, augmented data is generated from the original dataset using techniques such as band-stop filtering and temporal cutout. Subsequently, a ResNet model is pre-trained alongside a supervised contrastive loss model, learning the representation of the spectrogram image. In the training phase, a hybrid model is constructed by combining ResNet, initialized with weight values from the pre-trained model, and LSTM. This hybrid model extracts image features and time information to enhance prediction accuracy. The proposed method's effectiveness is validated using datasets from CHB-MIT and Seoul National University Hospital (SNUH). The method's generalization ability is confirmed through Leave-one-out cross-validation. From the experimental results measuring accuracy, sensitivity, and false positive rate (FPR), CHB-MIT was 91.90%, 89.64%, 0.058 and SNUH was 83.37%, 79.89%, and 0.131. The experimental results demonstrate that the proposed method outperforms the conventional methods.
In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. In single blind run-in (4 weeks) and double blind treatment period (8 weeks), patients were received matching placebo of aliskiren/amlodipine 150/5 mg tablet, aliskiren/amlodipine 150/2.5 mg tablet, aliskiren 150 mg tablet and two amlodipine 2.5 mg capsules once daily.